Loss in Life Expectancy after Surgical Aortic Valve Replacement

This study found after surgical aortic valve replacement (SAVR) patients had shorter life expectancy, compared against the general population. This loss in life expectancy was significant, especially in young patients. These results provide essential information to advice patients before and after SAVR.

Remodelado miocárdico reverso luego del reemplazo valvular

This is an observational national cohort study to assess long term relative survival and estimated loss in life expectancy after SAVR.

The study included 23528 patients undergoing SAVR with or without concomitant myocardial revascularization surgery in Sweden between 1995 and 2013 from the registry SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies). Life expectancy of the Swedish general population was estimated and matched by sex, age and year of surgery.

Over 19 years, researchers observed 21%, with and expected survival of 34%, and 63% relative survival. Loss in life expectancy was 1.9 years for the study population but varied with age. ≥80 patients only lost 0.4 years vs. 4.4 in <50 year olds.


Read also: Clinical Implications of the New Hypertension Guidelines.


There were no differences between men and women.

Conclusion

Patients undergoing surgical aortic valve replacement lose life expectancy compared against the general population, significantly, and especially the younger patients. This information is relevant to better advice our patients before and after SAVR.

Original Title: Loss in Life Expectancy After Surgical Aortic Valve Replacement. SWEDEHEART Study.

Reference: Natalie Glaser et al. J Am Coll Cardiol 2019;74:26–33.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...